Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DelveInsight | PRODUCT CODE: 1340038

Cover Image

PUBLISHER: DelveInsight | PRODUCT CODE: 1340038

Esophageal Cancer - Epidemiology Forecast - 2032

Published: Pre-Order
PAGES: 122 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 3950
PDF (2-3 user license)
USD 5925
PDF (Site License)
USD 7900
PDF (Global License)
USD 11850

Add to Cart

Key Highlights:

  • Esophageal cancer occurs in the esophagus - a long hollow muscular tube that transports food from the neck to the stomach. Esophageal cancer, also known as esophagus cancer, develops in the cells that line the esophagus and occurs when a malignant tumor arises in the esophagus lining.
  • Esophageal malignancies are often discovered as a result of a person's indications or symptoms. Examinations, testing, and a biopsy (a sample of esophageal cells) will be required to confirm the diagnosis if esophageal cancer is suspected. If cancer is discovered, more tests will be performed to establish the stage of the malignancy. The gold standard for identifying esophageal cancer is Gastroscopy.
  • Histologically, there are two forms of primary esophageal cancer: squamous cell carcinoma and adenocarcinoma; small cell carcinoma is an uncommon type of esophageal cancer. These several types of cancer arise in various types of cells in the esophagus. They evolve in distinct ways, necessitating therapeutic techniques tailored to each individual.
  • The staging system most often used for esophageal cancer is the American Joint Committee on Cancer (AJCC) TNM system, which is based on three key pieces of information, that is the extent of the tumor (T), spread to nearby lymph nodes (N) and spread (metastasis) to distant sites (M).
  • The exact cause of esophageal cancer is unknown; however, it is thought to be related to abnormalities (mutations) in the DNA of esophageal cells. The DNA of esophageal cancer cells frequently shows changes in many different genes; however, it is unclear if specific gene changes can be found in all esophageal cancers.
  • Regarding the epidemiology of esophageal cancer, in 2022, it was found that Japan accounted for the highest of the total diagnosed cases of esophageal cancer in the 7MM.
  • Among the EU4 countries, the least number of diagnosed cases of esophageal cancer were found in Italy, i.e., ~2,200 cases in the year 2022. These cases are expected to increase by 2032.
  • Esophageal Cancer, a relatively uncommon cancer, has very limited information and guidance available, with few opportunities for people to share experiences. This ends up leading to a lack of awareness about the disease. Its symptoms are also often mild until the cancer advances, and symptoms can be easily confused with other illnesses and digestive problems.

Report Summary:

The report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.

Esophageal Cancer Disease Understanding and Treatment

Esophageal Cancer Overview

Esophageal cancer develops when cancer cells form in the esophagus, a tube-like tissue that connects the throat and stomach. The esophagus transports food from the mouth to the stomach. The cancer begins in the esophagus's inner layer and can spread to other layers of the esophagus and other organs of the body (metastasis).

Typically, symptoms of esophageal cancer do not appear until the tumor has grown large enough to impede eating, swallowing, or digesting food. The most common symptom of esophageal cancer is difficulty swallowing, particularly a sensation that food is lodged in the throat; in some individuals, choking on food occurs. These symptoms develop with time, with greater discomfort while swallowing as the esophagus narrows due to cancer growth.

Esophageal Cancer diagnosis

Esophageal malignancies are often discovered by indications or symptoms. Exams, testing, and a biopsy (a sample of esophageal cells) will be required to confirm the diagnosis; if cancer is identified, more tests will help establish the extent (stage). When diagnosed late, esophageal cancer has a terrible prognosis; however, if diagnosed early, curative therapy is feasible. Before symptoms cause individuals to seek medical assistance, the condition slowly advances. Effective presymptomatic screening procedures may enhance disease outcomes. Recent research has shed light on the early detection of esophageal cancer using blood testing, sophisticated endoscopic imaging, and artificial intelligence.

Further details related to country-based variations are provided in the report…

Esophageal Cancer Epidemiology

As the market is derived using a patient-based model, the esophageal cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed incident cases of esophageal cancer , age-specific cases of esophageal cancer, histology-specific cases of esophageal cancer, gender-specific cases of esophageal cancer, mutation-specific cases of esophageal cancer, stage-specific cases of esophageal cancer and line wise treated cases of esophageal cancer in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

  • The total diagnosed incident cases of esophageal cancer in the US comprised ~20,000 cases in 2022 and are projected to increase by 2032 at a moderate CAGR, accounting for the second-highest diagnosed incident cases in the 7MM.
  • In 2022, as per the age-specific cases, the 65 and above age group accounted for the highest number of cases of esophageal cancer. In contrast, the <45 age group accounted for the least number of cases in the United States.
  • In the United States, ~16,000 cases of esophageal cancer were found in case of males, whereas females accounted for ~4,200 cases of esophageal cancer in 2022.
  • As per the Histology-specific incident cases of esophageal cancer, non-squamous esophageal cancer cases accounted for ~7,400 cases of esophageal cancer, whereas ~3,100 cases of squamous esophageal cancer were found in 2022 in the United Kingdom.

Esophageal Cancer Report Insights

  • Patient Population
  • Age-specific, gender-specific, histology-specific, mutation-specific and stage-specific distribution in esophageal cancer
  • Country-wise Epidemiology Distribution

Esophageal Cancer Report Key Strengths

  • Ten years Forecast
  • The 7MM Coverage
  • Esophageal Cancer Epidemiology Segmentation

Esophageal Cancer Report Assessment

  • Epidemiology Segmentation
  • Current Diagnostic Practices

Key Questions:

Epidemiology Insights

  • What are the disease risk, burdens, and unmet needs of esophageal cancer? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to esophageal cancer?
  • What is the historical and forecasted esophageal cancer patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
  • What is the diagnostic pattern of Esophageal Cancer?
  • Which clinical factors will affect Esophageal Cancer?
  • Which factors will affect the increase in the diagnosis of Esophageal Cancer?

Reasons to buy:

  • Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand the change in esophageal cancer cases in varying geographies over the coming years.
  • Detailed overview on age-specific, gender-specific, histology-specific, mutation-specific, stage-specific, and treated cases of esophageal cancer is included.
  • To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
  • Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Product Code: DIEI0075

Table of Contents

1. Key Insights

2. Report Introduction

3. Esophageal Cancer Market Overview at a Glance

  • 3.1. Patient Share (%) Distribution of Esophageal Cancer in 2019
  • 3.2. Patient Share (%) Distribution of Esophageal Cancer in 2032

4. Executive Summary of Esophageal Cancer

5. Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Histological Classification of Esophageal Cancer
  • 5.3. Stage-wise Classification of Esophageal Cancer
  • 5.4. Causes of Esophageal Cancer
  • 5.5. Risk Factors of Esophageal Cancer
  • 5.6. Signs and Symptoms of Esophageal Cancer
  • 5.7. Major Mutations in Esophageal Cancer
  • 5.8. Molecular abnormalities of EAC
  • 5.9. Molecular abnormalities of ESCC
  • 5.10. Diagnosis
  • 5.11. Imaging tests for Esophageal Cancer
  • 5.12. Diagnostic Algorithm
  • 5.13. Endoscopy for Cancer of the Esophagus
  • 5.14. Biopsy and Lab Tests for Cancer of the Esophagus
  • 5.15. Blood tests
  • 5.16. Differential Diagnosis
  • 5.17. Diagnostic Guidelines
    • 5.17.1. ESMO Clinical Practice Guideline for Diagnosis (2022)
    • 5.17.2. National Guidelines for the Diagnosis of Esophageal Carcinoma 2022 in China
    • 5.17.3. NCCN Guidelines for Esophageal Cancer (2022)

6. Epidemiology Methodology

7. Epidemiology and Patient Population

  • 7.1. Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Total Diagnosed Incident Cases of Esophageal Cancer in the 7MM
  • 7.4. Epidemiology Scenario in the United States
    • 7.4.1. Total Diagnosed Incident Cases of Esophageal Cancer in the US
    • 7.4.2. Age-specific Cases of Esophageal Cancer in the US
    • 7.4.3. Histology-specific Cases of Esophageal Cancer in the US
    • 7.4.4. Gender-specific Cases of Esophageal Cancer in the US
    • 7.4.5. Mutation-specific Cases of Esophageal Cancer in the US
    • 7.4.6. Stage-specific Cases of Esophageal Cancer in the US
    • 7.4.7. Linewise Treated Cases of Esophageal Cancer in the US
  • 7.5. Epidemiology Scenario in EU4 and the UK
    • 7.5.1. Total Diagnosed Incident Cases of Esophageal Cancer in EU4 and the UK
    • 7.5.2. Age-specific Cases of Esophageal Cancer in EU4 and the UK
    • 7.5.3. Histology-specific Cases of Esophageal Cancer in EU4 and the UK
    • 7.5.4. Gender-specific Cases of Esophageal Cancer in EU4 and the UK
    • 7.5.5. Mutation-specific Cases of Esophageal Cancer in EU4 and the UK
    • 7.5.6. Total Stage-specific Cases of Esophageal Cancer in EU4 and the UK
    • 7.5.7. Linewise Treated cases of Esophageal Cancer in EU4 and the UK
  • 7.6. Epidemiology Scenario in Japan
    • 7.6.1. Total Diagnosed Incident Cases of Esophageal Cancer in Japan
    • 7.6.2. Age-specific cases of Esophageal Cancer in Japan
    • 7.6.3. Histology-specific Cases of Esophageal Cancer in Japan
    • 7.6.4. Gender-specific Cases of Esophageal Cancer in Japan
    • 7.6.5. Mutation-specific Cases of Esophageal Cancer in Japan
    • 7.6.6. Stage-specific Cases of Esophageal Cancer in Japan
    • 7.6.7. Linewise Treated Cases of Esophageal Cancer in Japan

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

Product Code: DIEI0075

List of Tables

  • Table 1: Summary of Esophageal Cancer, Market and Epidemiology (2019-2032)
  • Table 2: Key Events
  • Table 3: AJCC Staging of Esophageal Cancer
  • Table 4: Total Diagnosed Incident Cases of Esophageal Cancer in the 7MM (2019-2032)
  • Table 5: Total Diagnosed Incident Cases of Esophageal Cancer in the US (2019-2032)
  • Table 6: Age-specific Cases of Esophageal Cancer in the US (2019-2032)
  • Table 7: Histology-specific Cases of Esophageal Cancer in the US (2019-2032)
  • Table 8: Gender-specific Cases of Esophageal Cancer in the US (2019-2032)
  • Table 9: Mutation-specific Cases of Esophageal Cancer in the US (2019-2032)
  • Table 10: Stage-specific Cases of Esophageal Cancer in the US (2019-2032)
  • Table 11: Linewise Treated Cases of Esophageal Cancer in the US (2019-2032)
  • Table 12: Total Diagnosed Incident Cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Table 13: Age-specific Cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Table 14: Histology-specific Cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Table 15: Gender-specific Cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Table 16: Mutation-specific cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Table 17: Total Stage-specific Cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Table 18: Linewise Treated Cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Table 19: Total Diagnosed Incident Cases of Esophageal Cancer in Japan (2019-2032)
  • Table 20: Age-specific Cases of Esophageal Cancer in Japan (2019-2032)
  • Table 21: Histology-specific Cases of Esophageal Cancer in Japan (2019-2032)
  • Table 22: Gender-specific Cases of Esophageal Cancer in Japan (2019-2032)
  • Table 23: Mutation-specific Cases of Esophageal Cancer in Japan (2019-2032)
  • Table 24: Stage-specific Cases of Esophageal Cancer in Japan (2019-2032)
  • Table 25: Linewise Treated Cases of Esophageal Cancer in Japan (2019-2032)

List of Figures

  • Figure 1: Understanding Gastroesophageal Reflux Induced Esophageal Tumorigenesis
  • Figure 2: Predominant Types of Primary Esophageal Cancers
  • Figure 3: Staging of Esophageal Cancer
  • Figure 4: The Risk Factors Profiles for Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma
  • Figure 5: Esophageal Cancer Warning Signs
  • Figure 6: Top Alterations in Esophageal Squamous Cell Carcinoma
  • Figure 7: Esophageal Cancer (Upper Endoscopy)
  • Figure 8: Algorithm for the Symptoms Suggestive of Esophageal Cancer
  • Figure 9: Imaging Differential Diagnosis
  • Figure 10: Esophagectomy
  • Figure 11: Total Diagnosed Incident Cases of Esophageal Cancer in the 7MM (2019-2032)
  • Figure 12: Total Diagnosed Incident Cases of Esophageal Cancer in the US (2019-2032)
  • Figure 13: Age-specific Cases of Esophageal Cancer in the US (2019-2032)
  • Figure 14: Histology-specific Cases of Esophageal Cancer in the US (2019-2032)
  • Figure 15: Gender-specific Cases of Esophageal Cancer in the US (2019-2032)
  • Figure 16: Mutation-specific Cases of Esophageal Cancer in the US (2019-2032)
  • Figure 17: Stage-specific Cases of Esophageal Cancer in the US (2019-2032)
  • Figure 18: Linewise Treated Cases of Esophageal Cancer in the US (2019-2032)
  • Figure 19: Total Diagnosed Incident Cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Figure 20: Age-specific Cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Figure 21: Histology-specific Cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Figure 22: Gender-specific Cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Figure 23: Mutation-specific Cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Figure 24: Total Stage-specific Cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Figure 25: Linewise Treated Cases of Esophageal Cancer in EU4 and the UK (2019-2032)
  • Figure 26: Total Diagnosed Incident Cases of Esophageal Cancer in Japan (2019-2032)
  • Figure 27: Age-specific Cases of Esophageal Cancer in Japan (2019-2032)
  • Figure 28: Histology-specific Cases of Esophageal Cancer in Japan (2019-2032)
  • Figure 29: Gender-specific Cases of Esophageal Cancer in Japan (2019-2032)
  • Figure 30: Mutation-specific Cases of Esophageal Cancer in Japan (2019-2032)
  • Figure 31: Stage-specific Cases of Esophageal Cancer in Japan (2019-2032)
  • Figure 32: Linewise Treated cases of Esophageal Cancer in Japan (2019-2032)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!